Affiliation:
1. CPL Associates, LLC, Amherst, New York
2. The School of Pharmacy, State University of New York at Buffalo, Buffalo, New York
Abstract
ABSTRACT
Data obtained from 318 adult patients treated under the linezolid compassionate-use protocol were used to develop a population model of the pharmacokinetics of intravenous and oral linezolid. All of the patients received 600 mg of linezolid every 12 h, intravenously and/or orally. Blood samples (2 to 10 per patient; median, 4) were obtained and assayed for linezolid by high-performance liquid chromatography. These data and patient covariates were modeled by iterative two-stage analysis, and model discrimination was done by Akaike's information criterion. Of the patient covariates considered (age, sex, ideal body weight, baseline serum albumin, hepatic or renal dysfunction, underlying malignancy, organ transplantation, surgical status, global severity of illness, site of infection, route of administration, and location of care [intensive-care unit, general floor, or outpatient]), only normalized creatinine clearance (CL
CR
) and body weight explained significant portions of the variance and were incorporated into the pharmacokinetic model. The final model included central and peripheral compartments with parallel capacity-limited (nonrenal) and first-order (renal [CL
R
]) clearances. Volumes and clearances were normalized to the ideal body weight, and CL
R
was modeled as proportional to CL
CR
. Compared to previously studied adult volunteers, intrinsic clearance was ∼60% higher and the maximum rate of metabolism was twice as high in these debilitated patients, resulting in lower area under the time-concentration curve (AUC) values (
P
< 0.001). The derived 24-h AUC, averaged over the first 7 days of treatment, ranged between 57 and 871 (median, 191) μg/ml · 24 h. Despite these variations, linezolid provided high rates of clinical cure, as well as microbiological success, in the patients treated in the compassionate-use program. The mechanism(s) of these pharmacokinetic differences is unknown and requires further mechanistic study.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Akaike, H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika66:237-242.
2. Ashtekar, D. R., R. Costa-Periera, T. Shrinivasan, R. Iyyer, N. Vishvanathan, and W. Rittel. 1991. Oxazolidinones, a new class of synthetic antituberculosis agents; in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis.14:465-471.
3. Birmingham M. C. C. R. Rayner A. K. Meagher S. F. Flavin D. H. Batts and J. J. Schentag. Linezolid in the treatment of multidrug-resistant Gram-positive infections: results of compassionate use experience. Clin. Infect. Dis. in press.
4. Prediction of Creatinine Clearance from Serum Creatinine
5. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp. Prog. Biomed.9:115-134.
Cited by
137 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献